Literature DB >> 15655318

Ultrapure dialysis fluid--direct and indirect benefits in dialysis therapy.

Ingrid Ledebo1.   

Abstract

The fluid quality description 'ultrapure' means practically free from bacteria and endotoxin. In quantitative terms it is defined as <0.1 CFU/ml and <0.03 EU/ml. The requirements on endotoxin as well as bacteria should be fulfilled, because these two entities are not strictly correlated. Ultrapure dialysis fluid can be prepared from standard quality fluid by a single step of controlled ultrafiltration. Recent clinical studies demonstrate that the use of ultrapure dialysis fluid in hemodialysis is associated with patient benefits indicating a less inflammatory state compared to hemodialysis with standard fluid. By applying one additional step of controlled ultrafiltration, ultrapure dialysis fluid can be further purified to such high microbiological quality that it can be used for infusion. This opens up the possibility for convective therapies, hemodiafiltration and hemofiltration, for which large volumes of sterile infusion solution are needed. With optimal application of these therapies, solute removal is enhanced, qualitatively as well as quantitatively, and fluid management is facilitated through improved hemodynamic stability. Copyright (c) 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15655318     DOI: 10.1159/000081869

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  3 in total

1.  Haemodiafiltration-optimal efficiency and safety.

Authors:  Ingrid Ledebo; Peter J Blankestijn
Journal:  NDT Plus       Date:  2009-11-05

2.  Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility.

Authors:  Gunilla Grundström; Anders Christensson; Maria Alquist; Lars-Göran Nilsson; Mårten Segelmark
Journal:  BMC Nephrol       Date:  2013-10-09       Impact factor: 2.388

3.  Benefits of the Nephros Dual Stage Ultrafilter in Chronic Hemodialysis Patients: Evidence for Improved ESA Responsiveness.

Authors:  Anthony Valeri; Bobby Lee; John Duffy; Robin Ferrer; Ronald Vilotta
Journal:  Case Rep Nephrol Dial       Date:  2016-01-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.